Related Experiment Video
Updated: Aug 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat
Christos Tikellis1, Peter J Wookey, Riccardo Candido
1Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.
Abstract:
The renin-angiotensin system (RAS) has an important role in the endocrine pancreas. Although angiotensin II has significant effects on cell proliferation and apoptosis, the contribution of the RAS to changes in islet structure and function associated with type 2 diabetes is yet to be defined. This study examined the specific effects of RAS blockade on islet structure and function in diabetes. Thirty-six male Zucker diabetic fatty (ZDF) rats, 10 weeks of age, were randomized to receive the angiotensin-converting enzyme inhibitor perindopril (8 mg/l in drinking water; n = 12), irbesartan (15 mg/kg via gavage; n = 12), or no treatment (n = 12) for 10 weeks. Results were compared with lean littermates (ZL) (n = 12) studied concurrently. ZDF rats had increased intra-islet expression of components of the RAS correlating with increased intraislet fibrosis, apoptosis, and oxidative stress. Disordered islet architecture, seen in ZDF rats, was attenuated after treatment with perindopril or irbesartan. Islet fibrogenesis was also diminished, as measured by picrosirius staining and expression of collagens I and IV. Gene expression of transforming growth factor-beta1 was increased in the ZDF pancreas (ZL, 1.0 +/- 0.1; ZDF, 2.0 +/- 0.3; P < 0.05) and reduced after blockade of the RAS (ZDF + P, 1.3 +/- 0.2; ZDF + I, 1.5 +/- 0.1; vs. ZDF, both P < 0.05). Improvements in structural parameters were also associated with functional improvements in first-phase insulin secretion. These findings provide a possible mechanism for the reduced incidence of new-onset diabetes that has been observed in clinical trials of RAS blockade.
Insights
Blocking the renin-angiotensin system (RAS) with perindopril or irbesartan improved pancreatic islet structure and function in diabetic rats. This suggests a potential mechanism for reducing new-onset diabetes in clinical trials.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- The renin-angiotensin system (RAS) plays a role in the endocrine pancreas.
- Angiotensin II affects cell proliferation and apoptosis, but its contribution to type 2 diabetes-related islet changes is unclear.
Purpose of the Study:
- To investigate the specific effects of RAS blockade on islet structure and function in a rat model of type 2 diabetes.
Main Methods:
- Thirty-six male Zucker diabetic fatty (ZDF) rats were treated for 10 weeks with an angiotensin-converting enzyme inhibitor (perindopril), an angiotensin II receptor blocker (irbesartan), or no treatment.
- Results were compared to lean littermates (ZL).
- Islet structure, fibrosis, apoptosis, oxidative stress, and gene expression (transforming growth factor-beta1) were assessed.
Main Results:
- ZDF rats showed increased intra-islet RAS components, fibrosis, apoptosis, and oxidative stress.
- Perindopril and irbesartan treatments attenuated disordered islet architecture and diminished islet fibrogenesis.
- RAS blockade reduced transforming growth factor-beta1 expression and improved first-phase insulin secretion.
Conclusions:
- RAS blockade improves structural and functional parameters of pancreatic islets in diabetic rats.
- These findings offer a potential mechanism for the observed reduction in new-onset diabetes in clinical trials involving RAS blockade.
